A ball kept slipping from a paralyzed man’s grasp. After receiving an experimental brain implant in Shanghai in November 2024, the patient, identified as Dong, practiced using his neural signals to control an air-powered glove. He eventually learned to pick up the ball reliably; about 20 days into training, he could lift a cup to drink, according to a 2025 interview with The Paper.
The breakthrough was measured in something decidedly ordinary: a sip of water.
From Statistical Significance to Commercial Authorization
On March 13, China's National Medical Products Administration (NMPA) approved an implanted hand-movement compensation system known as NEO for commercial use, marking what Reuters described as the world's first commercial authorization of an invasive brain–computer interface (BCI) medical device.
Developed by Shanghai-based Neuracle Medical Technology, also known as Borui Kang, in collaboration with Tsinghua University researchers, NEO had already undergone experimental implantation in patients with spinal-cord injuries. Its approval allows the technology to move beyond research trials, although widespread clinical availability is not immediate.
NEO does not repair a damaged spinal cord. Instead, a coin-sized implant collects electrical activity associated with intended hand movement through eight electrodes positioned outside the brain's protective dura mater, rather than penetrating brain tissue. Software translates these signals into commands, and a pneumatic glove supplies the physical grip.
The design reflects a deliberate compromise between capturing useful neural signals and minimizing direct injury to brain tissue. Neuracle's founder, Xu Hong, told The Paper in 2025 that balancing performance, power consumption, cost and surgical risk mattered more than maximizing electrode counts.
The approved patient population is narrow: adults aged 18 to 60 with qualifying cervical spinal-cord injuries involving vertebral levels C2–C6, diagnosed more than a year earlier and stable for at least six months. Patients must retain some upper-arm function but be unable to grasp objects independently.
The regulator reported substantial improvements in hand-grasping ability and quality of life. Neuracle told Chinese financial outlet Yicai that it had completed 36 implantation surgeries and that patients had achieved brain-controlled grasp assistance.
Yet the publicly disclosed evidence left important questions unanswered. The registered clinical study described a planned 32-participant, single-arm trial, involving six months of follow-up and intensive rehabilitation sessions. Without a comparison group or detailed long-term outcomes in the regulator's announcement, the durability and practical extent of the benefits remained uncertain.
The authorization also arrives amid a broader industrial push. China has designated BCIs a strategic future industry, while several provinces have begun piloting medical insurance coverage for BCI treatments, though coverage of NEO itself remained unclear. The regulator promised post-market surveillance, but its announcement did not specify long-term maintenance arrangements or how patients beyond specialist hospitals would obtain treatment.
Behind the First Grasp: Access, Maintenance, and Control
The paradox of a brain-controlled hand is that its user may gain physical independence while becoming dependent on an entire technological institution. Each movement relies on a functioning implant, decoder, glove and clinical support system. Consent to surgery occurs at a particular moment; living with its consequences is a continuing relationship.
Young people's encounters with neurotechnology already reveal this distinction.
Sanvi Pal, a Caltech undergraduate drawn to brain-interface research since high school, interviewed longtime implant participant James Johnson for The California Tech in 2024. She asked what researchers working with people who have brain implants ought to understand.
"It is good to allow the participants to give input," Johnson replied. He emphasized designing experimental tasks around activities he actually enjoyed, including art and video games.
For Noland Arbaugh, paralyzed at 22 while a college student, control carried an even more intimate meaning. The first recipient of Neuralink's experimental implant told The Guardian in 2025: "My brain is the last part of myself that I really feel I have control over."
His implant temporarily lost performance after electrode threads retracted, before software adjustments helped restore functionality. Although Neuralink uses a different implantation approach from NEO, his experience illustrates how personal autonomy can depend upon engineers continuing to provide support.
These concerns extend beyond individual devices. A 2024 U.S. Government Accountability Office assessment warned that some BCI research participants had lost access to device benefits when support or funding ended. UNESCO's 2025 neurotechnology ethics standard called for stronger safeguards for mental privacy, informed consent and affordability.
NEO decodes intended movements, not unrestricted private thoughts. Nevertheless, its neural recordings raise questions about data access, cybersecurity and whether patients can refuse secondary uses of their information without jeopardizing care.
For a generation accustomed to software updates and technological obsolescence, this represents an unusually consequential relationship with technology. A malfunctioning application can be deleted; a surgically implanted interface cannot simply be discarded.
The real test of this commercial breakthrough may therefore come years after the first successful grasp: whether the person who learns to raise a cup can continue doing so, with reliable support, affordable access and a meaningful say in the technology on which that freedom depends.
Explore more exclusive insights at nextfin.ai.
